antipyrine has been researched along with Injury, Myocardial Reperfusion in 17 studies
Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)
antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Edaravone suppressed plasma MCP-1, improved left ventricular ejection fraction, and reduced rehospitalization due to heart failure." | 9.14 | Effect of edaravone on plasma monocyte chemoattractant protein-1 levels in patients with acute myocardial infarction. ( Chitose, T; Fukuda, M; Kaikita, K; Nagata, T; Nagayoshi, Y; Nakamura, Y; Nako, H; Ogawa, H; Ogura, Y; Ohba, K; Shimomura, H; Soejima, H; Sugiyama, S; Tsujita, K; Yamada, Y; Yamaguchi, M; Yamashita, T, 2009) |
| "The effect of edaravone, a free radical scavenger, on long-term prognosis and its efficacy with regards to scavenging injurious free radicals in patients with acute myocardial infarction (AMI) was examined." | 9.12 | Long-term efficacy of edaravone in patients with acute myocardial infarction. ( Fukuda, M; Hokamaki, J; Kaikita, K; Kawano, H; Nagayoshi, Y; Nakamura, Y; Ogawa, H; Sakamoto, T; Shimomura, H; Tsujita, K; Yamashita, T; Yoshimura, M, 2006) |
| "This clinical pilot study was a randomized, controlled, open-label study in 80 patients with acute myocardial infarction and was designed to examine the effects of a novel free radical scavenger, edaravone." | 9.11 | Effects of edaravone on reperfusion injury in patients with acute myocardial infarction. ( Arai, H; Fukuda, M; Hida, S; Hokamaki, J; Kawano, H; Nagayoshi, Y; Nakamura, Y; Ogawa, H; Sakamoto, T; Shimomura, H; Tsujita, K; Yamashita, T; Yoshimura, M, 2004) |
| "Edaravone suppressed plasma MCP-1, improved left ventricular ejection fraction, and reduced rehospitalization due to heart failure." | 5.14 | Effect of edaravone on plasma monocyte chemoattractant protein-1 levels in patients with acute myocardial infarction. ( Chitose, T; Fukuda, M; Kaikita, K; Nagata, T; Nagayoshi, Y; Nakamura, Y; Nako, H; Ogawa, H; Ogura, Y; Ohba, K; Shimomura, H; Soejima, H; Sugiyama, S; Tsujita, K; Yamada, Y; Yamaguchi, M; Yamashita, T, 2009) |
| "The effect of edaravone, a free radical scavenger, on long-term prognosis and its efficacy with regards to scavenging injurious free radicals in patients with acute myocardial infarction (AMI) was examined." | 5.12 | Long-term efficacy of edaravone in patients with acute myocardial infarction. ( Fukuda, M; Hokamaki, J; Kaikita, K; Kawano, H; Nagayoshi, Y; Nakamura, Y; Ogawa, H; Sakamoto, T; Shimomura, H; Tsujita, K; Yamashita, T; Yoshimura, M, 2006) |
| "This clinical pilot study was a randomized, controlled, open-label study in 80 patients with acute myocardial infarction and was designed to examine the effects of a novel free radical scavenger, edaravone." | 5.11 | Effects of edaravone on reperfusion injury in patients with acute myocardial infarction. ( Arai, H; Fukuda, M; Hida, S; Hokamaki, J; Kawano, H; Nagayoshi, Y; Nakamura, Y; Ogawa, H; Sakamoto, T; Shimomura, H; Tsujita, K; Yamashita, T; Yoshimura, M, 2004) |
| "However, its effect on myocardial reperfusion injury after prolonged ischemia has not yet been demonstrated." | 1.29 | Effect of MCI-186 on postischemic reperfusion injury in isolated rat heart. ( Koide, S; Minhaz, U; Nakazawa, H; Shohtsu, A; Tanaka, M; Tsukamoto, H; Watanabe, K, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.76) | 18.2507 |
| 2000's | 10 (58.82) | 29.6817 |
| 2010's | 5 (29.41) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, W | 1 |
| Guo, Y | 1 |
| Yu, S | 1 |
| Wei, J | 1 |
| Jin, J | 1 |
| Zhang, G | 1 |
| Sun, Y | 1 |
| Wang, Y | 3 |
| Li, X | 1 |
| Li, T | 1 |
| Su, S | 1 |
| Xu, L | 2 |
| Shen, H | 1 |
| Zhang, GM | 1 |
| Li, XY | 1 |
| Sun, YY | 1 |
| Li, YZ | 1 |
| Liu, LF | 1 |
| Zhang, Y | 1 |
| Liao, H | 1 |
| Zhong, S | 1 |
| Gao, F | 1 |
| Chen, Y | 1 |
| Huang, Z | 1 |
| Lu, S | 1 |
| Sun, T | 1 |
| Wang, B | 1 |
| Li, W | 1 |
| Xu, H | 1 |
| Zheng, F | 1 |
| Shi, G | 1 |
| Zhang, YM | 1 |
| Liu, XH | 1 |
| Zhang, DW | 1 |
| Nakamura, Y | 3 |
| Yamada, Y | 1 |
| Shimomura, H | 3 |
| Nagayoshi, Y | 3 |
| Tsujita, K | 4 |
| Yamashita, T | 3 |
| Fukuda, M | 3 |
| Ohba, K | 1 |
| Nako, H | 1 |
| Ogura, Y | 1 |
| Chitose, T | 1 |
| Yamaguchi, M | 1 |
| Nagata, T | 1 |
| Soejima, H | 1 |
| Kaikita, K | 3 |
| Sugiyama, S | 1 |
| Ogawa, H | 4 |
| Miyazaki, Y | 1 |
| Endo, M | 1 |
| Horio, E | 1 |
| Miura, M | 1 |
| Hokimoto, S | 1 |
| Yamamuro, M | 1 |
| Iwawaki, T | 1 |
| Gotoh, T | 1 |
| Oike, Y | 1 |
| Wu, TW | 1 |
| Zeng, LH | 1 |
| Wu, J | 1 |
| Fung, KP | 1 |
| Rajesh, KG | 1 |
| Sasaguri, S | 1 |
| Suzuki, R | 1 |
| Maeda, H | 1 |
| Kawano, H | 2 |
| Hokamaki, J | 2 |
| Hida, S | 1 |
| Sakamoto, T | 2 |
| Yoshimura, M | 2 |
| Arai, H | 1 |
| Yagi, H | 1 |
| Horinaka, S | 1 |
| Matsuoka, H | 1 |
| Onimaru, S | 1 |
| Nakamura, K | 1 |
| Kariyazono, H | 1 |
| Ikeda, R | 1 |
| Ueno, T | 1 |
| Fukumoto, Y | 1 |
| Yabuki, A | 1 |
| Sakata, R | 1 |
| Yamada, K | 1 |
| Onogi, H | 1 |
| Minatoguchi, S | 1 |
| Chen, XH | 1 |
| Bao, N | 1 |
| Kobayashi, H | 1 |
| Misao, Y | 1 |
| Yasuda, S | 1 |
| Yamaki, T | 1 |
| Maruyama, R | 1 |
| Uno, Y | 1 |
| Arai, M | 1 |
| Takemura, G | 1 |
| Fujiwara, H | 1 |
| Sukmawan, R | 1 |
| Yada, T | 1 |
| Toyota, E | 1 |
| Neishi, Y | 1 |
| Kume, T | 1 |
| Shinozaki, Y | 1 |
| Mori, H | 1 |
| Ogasawara, Y | 1 |
| Kajiya, F | 1 |
| Yoshida, K | 1 |
| Minhaz, U | 1 |
| Tanaka, M | 1 |
| Tsukamoto, H | 1 |
| Watanabe, K | 1 |
| Koide, S | 1 |
| Shohtsu, A | 1 |
| Nakazawa, H | 1 |
| Wada, K | 1 |
| Fujibayashi, Y | 1 |
| Taniuchi, H | 1 |
| Tajima, N | 1 |
| Tamaki, N | 1 |
| Konishi, J | 1 |
| Yokoyama, A | 1 |
3 trials available for antipyrine and Injury, Myocardial Reperfusion
| Article | Year |
|---|---|
Effect of edaravone on plasma monocyte chemoattractant protein-1 levels in patients with acute myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Antipyrine; Biomarkers; Chemokine CCL2; Edaravone; Female; Fre | 2009 |
Effects of edaravone on reperfusion injury in patients with acute myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Antipyrine; Creatine Kinase; Creatine Kinase, MB Form; Edaravo | 2004 |
Long-term efficacy of edaravone in patients with acute myocardial infarction.
Topics: Acute Disease; Antipyrine; Arrhythmias, Cardiac; Edaravone; Free Radical Scavengers; Humans; Myocard | 2006 |
14 other studies available for antipyrine and Injury, Myocardial Reperfusion
| Article | Year |
|---|---|
Effects of edaravone on the expression of β-defensin-2 mRNA in lung tissue of rats with myocardial ischemia reperfusion.
Topics: Animals; Antipyrine; beta-Defensins; Blotting, Western; Creatine Kinase; Edaravone; Gene Expression | 2013 |
Local administration of lactic acid and a low dose of the free radical scavenger, edaravone, alleviates myocardial reperfusion injury in rats.
Topics: Animals; Antipyrine; Apoptosis; Dose-Response Relationship, Drug; Edaravone; Free Radical Scavengers | 2013 |
[Pharmacological postconditioning with lactic acid and low dose edaravone could attenuate myocardial reperfusion injury through mitochondrial pathway].
Topics: Animals; Antipyrine; Apoptosis; Cytochromes c; Disease Models, Animal; Edaravone; Ischemic Postcondi | 2013 |
Effect of N-n-butyl haloperidol iodide on ROS/JNK/Egr-1 signaling in H9c2 cells after hypoxia/reoxygenation.
Topics: Acetylcysteine; Antipyrine; Cell Hypoxia; Cell Line; Early Growth Response Protein 1; Edaravone; Gen | 2015 |
[Cardioprotective effect of edaravone pharmacological postconditioning on acute myocardial ischemia/reperfusion injury: experiment with rats].
Topics: Animals; Antipyrine; Disease Models, Animal; Edaravone; Free Radical Scavengers; Male; Myocardial Re | 2008 |
C/EBP homologous protein deficiency attenuates myocardial reperfusion injury by inhibiting myocardial apoptosis and inflammation.
Topics: Animals; Antipyrine; Apoptosis; Cells, Cultured; Chemokines; Cytokines; Disease Models, Animal; DNA- | 2011 |
Myocardial protection of MCI-186 in rabbit ischemia-reperfusion.
Topics: Animals; Antipyrine; Blood Pressure; Disease Models, Animal; Edaravone; Electrocardiography; Free Ra | 2002 |
Antioxidant MCI-186 inhibits mitochondrial permeability transition pore and upregulates Bcl-2 expression.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Antioxidants; Antipyrine; Atractyloside; Blo | 2003 |
Edaravone prevented deteriorated cardiac function after myocardial ischemia-reperfusion via inhibiting lipid peroxidation in rat.
Topics: Animals; Antipyrine; Edaravone; Free Radical Scavengers; Heart; Lipid Peroxidation; Male; Malondiald | 2005 |
Inhibitory effects of edaravone on the production of tumor necrosis factor-alpha in the isolated heart undergoing ischemia and reperfusion.
Topics: Analysis of Variance; Animals; Antipyrine; Blood Pressure; Blotting, Western; Edaravone; Free Radica | 2006 |
Edaravone reduces myocardial infarct size and improves cardiac function and remodelling in rabbits.
Topics: Animals; Antipyrine; Blood Pressure; Edaravone; Enzyme Inhibitors; Free Radical Scavengers; Gentisat | 2006 |
Edaravone preserves coronary microvascular endothelial function after ischemia/reperfusion on the beating canine heart in vivo.
Topics: Animals; Antipyrine; Blood Pressure; Blotting, Western; Coronary Circulation; Coronary Vessels; Dogs | 2007 |
Effect of MCI-186 on postischemic reperfusion injury in isolated rat heart.
Topics: Animals; Antioxidants; Antipyrine; Creatine Kinase; Edaravone; Free Radical Scavengers; Humans; In V | 1996 |
Effects of ischemia-reperfusion injury on myocardial single pass extraction and retention of Cu-PTSM in perfused rat hearts: comparison with 201T1 and 14C-iodoantipyrine.
Topics: Animals; Antipyrine; Carbon Radioisotopes; Copper Radioisotopes; In Vitro Techniques; Male; Myocardi | 1994 |